RAPT rallies as skin condition drug shows comparable efficacy to Roche's drug

Rapt Therapeutics

20/10/2025 17:44

Updates

** Shares of Rapt Therapeutics RAPT.O rise as much as 44.5% to $42.39, its highest in more than a year

** Drug developer says its experimental drug to treat chronic spontaneous urticaria (CSU) showed comparable efficacy and safety to Roche ROG.S and Novartis' NOVN.S Xolair in a mid-stage trial in China

** The 137-patient study tested safety and efficacy of the drug, RPT904, dosed at intervals of 8 weeks and 12 weeks, compared to Xolair dosed every 4 weeks - RAPT

** CSU, also known as chronic hives, is a skin condition that causes recurring itchy red patches without a known trigger, often lasting for months

** The study was not a formal non-inferiority study and no statistical hypothesis was tested - RAPT

** Nearly 46% of patients on RPT904 had no symptoms of hives at week 16, vs 33.3% on Xolair - RAPT

** Including session's move, stock up ~171% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.pandey@thomsonreuters.com))